Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Creatinine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6,490 result(s) found for: Creatinine. Displaying page 1 of 325.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-000308-82 Sponsor Protocol Number: oxalate01 Start Date*: 2017-02-08
    Sponsor Name:Universitair Ziekenhuis Brussel
    Full Title: Lanthanum Carbonate (Fosrenol®) to reduce oxalate excretion in patients with secondary hyperoxaluria and nephrolithiasis: a short-term, prospective, open-label, efficacy and safety clinical trial
    Medical condition: Urolithiasis and secondary hyperoxaluria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003890-23 Sponsor Protocol Number: Cisplatin Start Date*: 2021-02-23
    Sponsor Name:Erasmus MC Cancer Institute
    Full Title: The nephroprotective effect of short hydration during cisplatin treatment in head and neck cancer patients.
    Medical condition: Cisplatin induced nephrotoxicity
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003022-32 Sponsor Protocol Number: CL012_140 Start Date*: 2019-10-12
    Sponsor Name:ChemoCentryx, Inc.
    Full Title: An Open Label, Intra-Subject Dose Escalation Study of CCX140-B in Subjects with Primary Focal Segmental Glomerulosclerosis (FSGS) and Nephrotic Syndrome
    Medical condition: Primary Focal Segmental Glomerulosclerosis (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003198-17 Sponsor Protocol Number: UZB_20160728 Start Date*: 2016-09-29
    Sponsor Name:Universitair Ziekenhuis Brussel Vrije Universiteit Brussel
    Full Title: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome
    Medical condition: Treatment of Idiopathic Nephrotic Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000535-18 Sponsor Protocol Number: ML17632 Start Date*: 2005-05-18
    Sponsor Name:Roche Pharma (Schweiz) AG
    Full Title: Prospective, multicenter study to evaluate the renal safety of 6 mg ibandronic acid infusions over 15 min or 60 min in patients with metastatic bone disease due to breast cancer.
    Medical condition: The target population for this trial are female patients with primary breast cancer with metastatic bone disease.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004917-41 Sponsor Protocol Number: WX17801 Start Date*: 2005-09-05
    Sponsor Name:Aspreva International Ltd.
    Full Title: A prospective, randomized, active controlled, parallel group, multi-center trial to assess the efficacy and safety of mycophenolate mofetil (MMF) in inducing response and maintaining remission in s...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    4.1 10025140 Low
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) PT (Completed) AT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-005182-37 Sponsor Protocol Number: OT-0401 Start Date*: 2005-07-25
    Sponsor Name:Curatis Pharma GmbH
    Full Title: A double-blind, randomized, placebo-controlled, multicenter phase III study of intravenous terlipressin in patients with hepatorenal syndrome type 1
    Medical condition: Hepatorenal Syndrome Type 1
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019846 Hepatorenal syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000761-40 Sponsor Protocol Number: AP-recAP-AKI-02-01 Start Date*: 2014-10-22
    Sponsor Name:AM-Pharma B.V.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Four-Arm, Parallel-Group, Proof of Concept, and Dose-Finding Adaptive Phase 2a/2b Study to Investigate the Safety, Tolerability and Efficacy and Effe...
    Medical condition: Sepsis-Associated Acute Kidney Injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) CZ (Completed) AT (Completed) NL (Completed) ES (Completed) IT (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000234-33 Sponsor Protocol Number: PKCARBOB Start Date*: 2014-09-30
    Sponsor Name:rijnstate hospital, the netherlands
    Full Title: PHARMACOKINETICS OF CARBOPLATIN AFTER ADJUSTED DOSING FOR HIGH BMI, LOW SERUM CREATININE, AND MAXIMAL RENAL FUNCTION
    Medical condition: non-small cell lung cancer, small cell lung cancer, ovarian cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-004578-40 Sponsor Protocol Number: SSAT066 Start Date*: 2015-01-26
    Sponsor Name:St Stephen's AIDS Trust
    Full Title: A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal ...
    Medical condition: HIV
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017642-32 Sponsor Protocol Number: Nyreprofylakse1 Start Date*: 2010-02-16
    Sponsor Name:Odense University Hospital
    Full Title: Nyreprofylakse ved ST-segment elevation myokardie infarkt og primær PCI
    Medical condition: Decreased renal function in patients with STEMI undergoing acute PCI
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2012-001314-42 Sponsor Protocol Number: IM103116 Start Date*: 2013-09-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (belatacept)-based Immunosuppression
    Medical condition: Maintenance of renal transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-000627-26 Sponsor Protocol Number: FK04 Start Date*: 2008-09-29
    Sponsor Name:Leiden University Medical Center
    Full Title: Conversion from cyclosporine to tacrolimus followed by randomized C0 or Bayesian monitoring using the C4 timepoint The effect on kidney function
    Medical condition: Effect of immunosuppressive medication on renal function following livertransplantation
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000604-14 Sponsor Protocol Number: SPP301CRD15 Start Date*: 2005-08-24
    Sponsor Name:Speedel Pharma Ltd.
    Full Title: A randomised, double blind, placebo controlled, parallel group study to assess the effect of the endothelin receptor antagonist avosentan on time to doubling of serum creatinine, end stage renal di...
    Medical condition: Diabetic Nephropathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FI (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) LT (Prematurely Ended) SE (Prematurely Ended) SK (Completed) DE (Prematurely Ended) EE (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing) LV (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-003481-14 Sponsor Protocol Number: 3004 Start Date*: 2014-03-07
    Sponsor Name:National Institute of Diabetes and Digestive and Kidney Diseases
    Full Title: Study of allopurinol to prevent GFR loss in type 1 diabetes
    Medical condition: Type 1 diabetes, microalbuminuria or macroalbuminuria and mildly impaired kidney function.
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004848 10037827 Raised serum uric acid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005856-32 Sponsor Protocol Number: RITULUP Start Date*: 2012-05-21
    Sponsor Name:Fundación Progreso y Salud
    Full Title: Comparison of the efficacy of two rituximab treatment regimens in patients with lupus nephropathy resistant to conventional treatment
    Medical condition: Long-term relapse after treatment of lupus nephritis (LN) resistant to conventional treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004212-21 Sponsor Protocol Number: AMAG-423-201 Start Date*: 2019-05-24
    Sponsor Name:AMAG Pharmaceuticals, Inc.
    Full Title: A Phase 2b/3a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of AMAG-423, a Digoxin Immune Fab, in Antepartum Subjects with Severe Pree...
    Medical condition: Severe Preeclampsia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10040444 Severe pre-eclampsia LLT
    Population Age: Adults Gender: Female
    Trial protocol: PL (Temporarily Halted) ES (Prematurely Ended) GB (Prematurely Ended) BE (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001083-16 Sponsor Protocol Number: DCR-PHXC-203 Start Date*: 2021-10-04
    Sponsor Name:Dicerna Pharmaceuticals Inc
    Full Title: A Phase 2 Open-Label Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Nedosiran in Pediatric Patients from Birth to 11 Years of Age with Primary Hyperoxaluria and Relativ...
    Medical condition: Primary Hyperoxaluria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10020703 Hyperoxaluria PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) ES (Ongoing) PL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000511-25 Sponsor Protocol Number: 20040114 Start Date*: 2004-10-08
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open Label, Active Controlled Study of AMG 162 in Subjects with Advanced Cancer Currently Being Treated with Intravenous Bisphosphonates
    Medical condition: Bone metastases of solid tumors (except lung) or multiple myeloma bone disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000298-22 Sponsor Protocol Number: PRENECAL Start Date*: 2012-12-05
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Study to assess the efficacy and safety of oral potassium citrate on the Prevention of nephrocalcinosis in extreme premature: a clinical trial, randomized, double-blind placebo controlled trial. St...
    Medical condition: incidence of nephrocalcinosis in extremely preterm infants
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10029146 Nephrocalcinosis PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:40:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA